Highlights Newsletter 4
This newsletter presents you the following key sessions:
1. Podcast with dr Talha Munir about ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab for first-line
treatment of chronic lymphocytic leukemia: the GLOW study
2. Axicabtagene ciloleucel: potential new second-line standard of care for patients with relapsed/refractory
large B-cell lymphoma
3. Adding ivosidenib to azacitidine improves clinical outcomes in untreated, IDH-mutation positive AML
patients who are unfit for intensive chemotherapy
4. Mosunetuzumab: effective and well-tolerated in the treatment of relapsed/refractory follicular lymphoma
5. Polatuzumab vedotin plus R-CHP as first line treatment for patients with diffuse large B-cell lymphoma